|
|
|
|
|
|
|
J Rural Health 2010,Dec,21;26(1):100-4; (PMID: 20105276)
CONTEXT: Asthma affects over 15% of Australian Aboriginal people. Compliance in asthma management is poor. Interventions that will increase compliance are required.[...]
|
|
|
Ethn Dis 2010,Dec,21;20(1 Suppl 2):S2-1-8; (PMID: 20629240)
[...]These sustained, institutionalized relationships unite resources and both community and scientific expertise in a community-partnered participatory research model to address multiple health problems in the community, including preterm birth, HIV, asthma, depression, and diabetes. The HAAF participatory process builds on existing community resiliency and resources and on centuries of self-help, problem-solving, cooperative action, and community activism within the African American community.[...]
|
|
|
Steroids 2010,Dec,01;75(12):918-25; (PMID: 20493895)
[...]Resistance to glucocorticoids is an important medical problem, since it limits the efficacy of glucocorticoids when they are used to treat immune-related diseases like asthma and rheumatoid arthritis. Glucocorticoid resistance also contributes to the pathogenesis of other diseases, like [...]
|
|
|
Environ Int 2010,Oct,01;36(7):788-99; (PMID: 20557934)
[...] exposure studies below 1 mg/m(3), and epidemiological associations between FA concentrations and exacerbation of asthma in children and adults are encumbered by complex exposures. Neither experimental nor epidemiological studies point to major differences in susceptibility to [...]
|
|
|
Inflammation 2010,Oct,01;33(5):320-4; (PMID: 20195729)
[...]Despite the continuing interest in DHEA replacement therapy, our knowledge of its effects upon asthma is very limited. DHEA is able to reverse cytokine imbalances associated with asthma, may prevent and attenuate [...]
|
|
|
Inflammation 2010,Oct,01;33(5):334-43; (PMID: 20195728)
[...]Chemokines for neutrophils such as growth-related oncogene-alpha (GRO-alpha) are important in patients with refractory or severe asthma. Prostaglandin I(2) (PGI(2)) analogues were regarded as potential treatments for asthma.[...]
|
|
|
Pulm Pharmacol Ther 2010,Oct,01;23(5):384-8; (PMID: 20542129)
[...]Adherence to daily anti-inflammatory therapy, the cornerstone being inhaled corticosteroids (ICSs), is critical for the control of persistent asthma. Many factors, both behavioral and treatment-related, can affect treatment adherence. In the pediatric population, adherence is often the responsibility of parents/caregivers.[...]
|
|
|
Pulm Pharmacol Ther 2010,Oct,01;23(5):425-31; (PMID: 20457270)
[...]thromboxane A(2) (TXA(2)) are important mediators in inflammatory lung diseases such as bronchial asthma and idiopathic pulmonary fibrosis (IPF). We examined the effects of inhaled KP-496, a novel dual antagonist of the cysLTs and [...]
|
|
|
Pulm Pharmacol Ther 2010,Oct,01;23(5):432-7; (PMID: 20416389)
RATIONALE: Treatment of severe asthma may be difficult despite the use of several medications including parenteral corticosteroids. Intravenous magnesium sulfate[...]
|
|
|
J Immigr Minor Health 2010,Oct,01;12(5):640-51; (PMID: 18998210)
Asthma and obesity-related health problems disproportionately impact low-income ethnic minority communities residing in urban areas. Environmental risk factors, particularly those related to housing and indoor air, may impact the development or exacerbation of [...]
|
 1 2 3 4 5 6 7 8 
|
|
|
|
|
